Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH Agonist Plus Letrozole vs GnRH Agonist Alone in Adenomyosis for FET
NCT06913075Not yet recruiting
- Sponsor
- Indira IVF
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of letrozole in adenomyosis (2 arms), sponsored by Indira IVF. Primary endpoint: Ongoing pregnancy rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
letrozole
03
Conditions
adenomyosis
Beyond the preview
Go deeper on NCT06913075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913075.